リスクのある 1 型糖尿病の研究におけるテクノロジーの開始 (STAR-T1D)
リスクのある 1 型糖尿病 (STAR-T1D) 研究における技術の開始
Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c ≥8.0%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Estelle M Everett, MD, MHS
- 電話番号:310-267-0625
- メール:eeverett@mednet.ucla.edu
研究場所
-
-
California
-
Santa Monica、California、アメリカ、90404
- 募集
- UCLA
-
コンタクト:
- Rebecca Lopez, BA
- 電話番号:(310) 882-0033
- メール:rebeccalopez@mednet.ucla.edu
-
コンタクト:
- Erin E Shaw, B.S.
- メール:EEShaw@mednet.ucla.edu
-
Sylmar、California、アメリカ、91342
- 募集
- Olive View-UCLA Medical Center
-
コンタクト:
- Hugo Torres, MD
- 電話番号:747-210-3000
- メール:HATorres@mednet.ucla.edu
-
Torrance、California、アメリカ、90502
- 募集
- Harbor-UCLA Medical Center
-
コンタクト:
- Joyce A Graham
- 電話番号:(310) 222-1870
- メール:jgraham@lundquist.org
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Type 1 Diabetes
- A1c ≥ 8.0%
- Not insulin pump user
- Primary language of English or Spanish
- Have medical insurance coverage
Exclusion Criteria:
- No measured A1c in the past year
- Have comorbidities that can result in inaccurate hemoglobin A1c
- Have cognitive, physical or mental impairment precluding diabetes technology use
- Limited life expectancy (<1 year)
- Pregnancy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Hybrid Closed Loop Insulin Pump System
Participants will meet 1:1 with our CDE for at least 6 sessions over 6 weeks. Sessions will cover self-management basics, carb counting, CGM interpretation, hypoglycemia and hyperglycemia management and troubleshooting device issues. The investigators will follow up with participants in 24 and 72 hours after CGM and insulin pump initiation, respectively, to answer any device related questions that may arise in between sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects and evaluate device and safety issues associated with pump settings in the HCL arm. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
Patients will be started on an automated insulin delivery system. |
|
介入なし:Control
Participants in the control arm will receive diabetes education at a similar frequency as the intervention group. Diabetes education for the control group will be a combination of in-person visits with the CDE and telephone brief diabetes education sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of screened participants that are eligible
時間枠:6 months
|
Eligible among screened, enrolled among eligible, excluded among screened (and why) based on screening, recruitment and enrollment data. |
6 months
|
|
Proportion of enrolled participants that are randomized
時間枠:6 months
|
Randomized among enrolled, and receiving allocated intervention among randomized. |
6 months
|
|
Proportion of average time delay to enrollment
時間枠:6 months
|
Average time delay from screening to enrollment. |
6 months
|
|
Proportion of retention among participants randomized to the Intervention Group
時間枠:6 months
|
Retention among participants receiving allocated intervention after being randomized and discontinued intervention among randomized. |
6 months
|
|
Proportion of retention among participants randomized
時間枠:6 months
|
Participants lost to follow-up among those initially randomized. |
6 months
|
|
Proportion of retention among participants randomized
時間枠:6 months
|
Retention rates by participants completing all research assessments among randomized. |
6 months
|
|
Number of participants who adhere to assigned treatment
時間枠:6 months
|
Treatment-specific adherence, Adherence to study protocol and Proportion of planned assessments that are completed. Fidelity, which pertains to guaranteeing that the intervention is delivered in accordance with the established protocol, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. Adherence, which relates to the extent to which participants follow the treatment and study protocol, as well as the proportion of planned assessments completed, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. |
6 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in A1c
時間枠:6 months
|
Serum Hemoglobin A1c laboratory measurement |
6 months
|
|
Episodes and % of time with severe hypoglycemia ( BG <54 mg/dl)
時間枠:6 months
|
Hypoglycemia will be measure by combining CGM metrics and glucometer to report severe hypoglycemia in mg/dl. |
6 months
|
|
Mean Diabetes Ketoacidosis Episodes Incidence
時間枠:6 months
|
Assess instances of diabetic ketoacidosis through participant surveys and comprehensive chart reviews. |
6 months
|
|
ED visits/Hospitalizations Number of diabetes related ED visits or hospitalizations
時間枠:6 months
|
Number of diabetes related ED visits or hospitalizations |
6 months
|
|
Treatment Burden and Satisfaction: Diabetes Distress
時間枠:6 months
|
Assessing treatment burden through the Type 1 Diabetes Distress Assessment System T1DDAS, which comprises eight questions and evaluates ten prevalent sources of diabetes distress in adults with type 1 diabetes. The score indicates the level of diabetes distress reported by the respondent, with higher scores indicating greater intensity. The core scale scoring ranges 1 to 5. This scale assesses each of ten common Sources of diabetes distress for adults with type 1 diabetes: Financial Worries, Interpersonal Challenges, Management Difficulties, Shame, Hypoglycemia Concerns, Healthcare Quality, Lack Of Diabetes Resources, Technology Challenges, Burden To Others, Worries About Complications. The higher the score, the more impactful that Source is likely to be in contributing to diabetes distress for this individual with the minimum value being 1 and maximum value being 5. |
6 months
|
|
Treatment Burden and Satisfaction: Insulin Treatment Satisfaction
時間枠:6 months
|
Assessed treatment burden and satisfaction using the Insulin Treatment Satisfaction Questionnaire (ITSQ), consisting of 22 questions among 5 content clusters with a score from 0 to 100% where a higher score indicates greater satisfaction with insulin treatment. The scale explores perceptions of current insulin treatment and its impact on daily life. |
6 months
|
|
Treatment Burden and Satisfaction: Glucose Monitoring System Satisfaction (GMSS)
時間枠:6 months
|
Examined treatment burden and satisfaction employing the Glucose Monitoring System Satisfaction Survey (GMSS), comprising 15 questions divided into four subcategories: openness, emotional burden, behavioral burden and trust. Higher scores within each subcategory denote either greater satisfaction or burden, depending on the specific aspect assessed with the minimum value being 1 and maximum value being 5. The total scare has a minimum value of 1 and maximum value of 15 with higher scores indicating greater satisfaction. The scores are obtained by calculating the mean for each. |
6 months
|
|
Treatment Burden and Satisfaction: Motivation and Attitudes Towards Changing Health (MATCH)
時間枠:6 months
|
Assessed treatment burden and satisfaction using the Motivation and Attitudes towards Health Scale (MATCH), consisting of nine questions categorized into four subgroups: willingness to make changes, perceived ability to make or maintain changes, feeling changes are worthwhile, and overall mean/average of willingness, able, and worthwhile. Scores are calculated by determining the mean or average response within each category with higher scores meaning a better outcome. WILLINGNESS: minimum value is 1 and maximum value is 5. ABLE: minimum value is 1 and maximum value is 5. WORTHWHILE: minimum value is 1 and maximum value is 5. TOTAL SCALE: minimum value is 1 and maximum value is 9. |
6 months
|
協力者と研究者
協力者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 22-000236
- 5K23DK132482-02 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。